Effect of Aldosterone on Energy Starvation in Heart Failure

Completed · Phase 4

Conditions studied: Heart Failure, Nonischemic Dilated Cardiomyopathy

In brief

We plan to study the concept of "energy starvation" in heart failure by evaluation of patients with nonischemic dilated cardiomyopathy (NIDCM) (heart failure with reduced heart pump function due to causes other than heart attack). We will use a combination of positron emission tomography and magnetic resonance imaging to study metabolism, anatomy, function, blood flow and efficiency, before and after 6 months' treatment with the drug spironolactone which blocks the deleterious effects of the hormone aldosterone on the myocardium (heart muscle).

Key facts

Study ID

NCT00574119

Run by

Vanderbilt University

People needed

16

Starts

2007-12-01

Expected to finish

2012-07-01

Last updated by the study team

2019-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Nonischemic dilated cardiomyopathy
• Left ventricular ejection fraction 35% or less
• Stable heart failure symptoms
• Able to undergo both positron emission tomography and magnetic resonance imaging with gadolinium
• Able to tolerate treatment with spironolactone

You may not qualify if…

• Serum potassium >5.0
• Serum creatinine >2.5
• Contraindications to magnetic resonance imaging such as internal cardioverter-defibrillator.

Where it is running

• Vanderbilt Heart and Vascular Institute — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.